Evidence map›Paper›PMID 34011587›Full record

ArticleBMJ open2021

Cost-effectiveness of home versus hospital management of children at onset of type 1 diabetes: the DECIDE randomised controlled trial.

Zoe McCarroll, Julia Townson, Timothy Pickles, John W Gregory, Rebecca Playle, Michael Robling, Dyfrig A Hughes

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zoe McCarrollSchool of Medicine, Cardiff University, Cardiff, UK.
Julia TownsonCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK townson@cf.ac.uk.ORCID 0000-0001-8679-3619
Timothy PicklesCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
John W GregorySchool of Medicine, Cardiff University, Cardiff, UK.
Rebecca PlayleCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Michael RoblingCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.ORCID 0000-0002-1004-036X
Dyfrig A HughesCentre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.ORCID 0000-0001-8247-7459
Cardiff University · GBBangor University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this economic evaluation was to assess whether home management could represent a cost-effective strategy in the patient pathway of type 1 diabetes (T1D). This is based on the Delivering Early Care In Diabetes Evaluation trial (ISRCTN78114042), which compared home versus hospital management from diagnosis in childhood diabetes and found no statistically significant difference in glycaemic control at 24 months.

designCost-effectiveness analysis alongside a randomised controlled trial.

settingEight paediatric diabetes centres in England, Wales and Northern Ireland.

participants203 clinically well children aged under 17 years, with newly diagnosed T1D and their carers. OUTCOME MEASURES: The base-case analysis adopted n National Health Service (NHS) perspective. A scenario analysis assessed costs from a broader societal perspective. The incremental cost-effectiveness ratio (ICER), expressed as cost per mmol/mol reduction in glycated haemoglobin (HbA1c), was based on the mean difference in costs between the home and hospital groups, divided by mean differences in effectiveness (HbA1c). Uncertainty was considered in terms of the probability of cost-effectiveness.

resultsAt 24 months postintervention, the base-case analysis showed a difference in costs between home and hospital, in favour of home management (mean difference -£2,217; 95% CI -£2825 to -£1,609; p<0.001). Home care dominated, with an ICER of £7434 (saved) per mmol/mol reduction of HbA1c. The results of the scenario analysis also favoured home management. The greatest driver of cost differences was hospitalisation during the initiation period.

conclusionsHome management from diagnosis of children with T1D who are medically stable represents a less costly approach for the NHS in the UK, without impacting clinical effectiveness. TRIAL REGISTRATION NUMBER: ISRCTN78114042.

Indexed as

Diabetes Mellitus, Type 1ChildCost-Benefit AnalysisEnglandHospitalsHumansNorthern IrelandQuality-Adjusted Life YearsQuality of LifeRandomized Controlled Trials as TopicState MedicineWalesdiabetes & endocrinologyhealth economicspaediatric endocrinology

Identifiers

PMID34011587
PMCPMC8137197
OpenAlexW3163112646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.